BioTek moves all software development in-house

Biotek reached end of a years-long project to bring all software development and support in-house.

Register for free to listen to this article
Listen with Speechify
WINOOSKI, Vt.—When micro­plate specialist BioTek Inc. rolled out its new Gen5 software package this summer, it marked more than just another prod­uct introduction. Designed to replace the KC line of software the company offered for all of BioTek's microplate readers, Gen5 was not only a switch to a more robust, user-friendly package, but it also marked the end-point of a years-long proj­ect that saw BioTek successfully bring all software development and support in-house.
"In the mid-90s we made the decision to partner with an external software development firm in France," explains Briar Alpert, BioTek's president and CEO. "This decision was made because our internal software resources were committed to ongoing projects and we had a need to quickly develop a data-reduction software package capable of supporting our micro­plate detection product line."
While the relationship with the outside software vendor was successful in developing the KC line of software which Alpert says was "market-leading", by 2000, Alpert noticed that the data-reduction software used for the company's instrumen­tation line was often a decid­ing factor in whether custom­ers would buy the instruments themselves.
"At this point, we decided that it was in BioTek's strategic best interest to own, internally understand and directly con­trol all the intellectual property associated with the software that works with our instrumen­tation," he says.
With that, the company set in motion the tasks of transferring the technology from its software partner and of building a dedi­cated software development team to work on the launch of what became the Gen5 product.
While the company already had an active software development function within the company, the move would require creating an independent software department, the need to transition existing soft­ware engineers to the project and the hiring of a project manager and two software engineers. In all, at the height of the development of Gen5, there were 13 people work­ing on the project, ten of whom were new hires for the company, including the chief engineer from its former software vendor, Alpert says.
As is often the case, there was more work to do than initially thought. "Our intention was to build the next generation of soft­ware using the architecture our vendor used for KC," says Lenore Beuhrer, product manager. "But when we completed the technolo­gy transfer, we saw that this would not work and we would need to build the entire package from the ground up."
But even with the extra work, the benefits for the company, and ultimately its customers, should be apparent. "Having the extra resources and developing Gen5 ourselves makes it easier to sup­port our customers and to react quickly to what their needs are," says Beuhrer. "It also allows us to provide regular upgrades to our software, which customers expect and is something we weren't able to do easily using an outside ven­dor."
For Alpert, the significant expense of developing a dedicated software development team is well worth it. "In hindsight, it should have been done sooner. But we were very satisfied with the work being performed by our external software house and we had other more pressing activities that took priority," he says. "As the data-reduction software became a more important portion of our total offering, we felt that we simply had to understand, own and control this functionality."

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue